177843-72-0

Basic information

• Product Name: 1H-Benzimidazol-5-amine, 6-methyl- (9CI)
• Synonyms: 1H-Benzimidazol-5-amine, 6-methyl- (9CI);6-Methyl-1H-benzo[d]iMidazol-5-aMine;5-methyl-1H-benzo[d]imidazol-6-amine 6-methyl-3H-benzo[d]imidazol-5-amine 1H-Benzimidazol-5-amine, 6-methyl- (9CI);5-methyl-1H-Benzimidazol-6-amine
• CAS NO: 177843-72-0
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.17716
• Product Categories: BENZIMIDAZOLE
• Mol File: 177843-72-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazol-5-amine, 6-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazol-5-amine, 6-methyl- (9CI)(177843-72-0)
• EPA Substance Registry System: 1H-Benzimidazol-5-amine, 6-methyl- (9CI)(177843-72-0)

Safety Data

• Hazardous Substances Data: 177843-72-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazol-5-amine, 6-methyl(9CI) is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and biological activities make it a promising candidate for the treatment of various diseases, including potential drug targets for conditions that require novel therapeutic approaches.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Benzimidazol-5-amine, 6-methyl(9CI) is utilized as a key component in the synthesis of pesticides and other agrochemical products. Its incorporation can enhance the effectiveness of these products, contributing to improved crop protection and yield.
Used in Organic Synthesis:
1H-Benzimidazol-5-amine, 6-methyl(9CI) serves as a versatile building block in organic synthesis, allowing for the creation of a wide array of organic compounds with diverse applications. Its reactivity and structural features make it an essential component in the synthesis of complex organic molecules for various industries, including pharmaceuticals, materials science, and specialty chemicals.

Upstream product

• 61587-90-4 5-methyl-6-nitro-1H-1,3-benzodiazole 
• 65958-37-4 4-methyl-5-nitrobenzene-1,2-diamine 
• 5267-27-6 5-amino-2,4-dinitrotoluene 
• 537-92-8 3-Methylacetanilide 
• 614-97-1 5-methylbenzimidazole 

Relevant articles and documents

Bicyclic heterocyclic anthranilic diamides as ryanodine receptor modulators with insecticidal activity

The diamide insecticides act on the ryanodine receptor (RyR). The synthesis of various bicyclic anthranilic derivatives is reported. Their activity against the insect ryanodine receptor (RyR) and their insecticidal activity in the greenhouse is presented,

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor

Despite the progress of the past two decades, there is still considerable need for safe, efficacious drugs that target human immunodeficiency virus (HIV). This is particularly true for the growing number of patients infected with virus resistant to currently approved HIV drugs. Our high throughput screening effort identified a benzophenone template as a potential nonnucleoside reverse transcriptase inhibitor (NNRTI). This manuscript describes our extensive exploration of the benzophenone structure-activity relationships, which culminated in the identification of several compounds with very potent inhibition of both wild type and clinically relevant NNRTI-resistant mutant strains of HIV. These potent inhibitors include 70h (GW678248), which has in vitro antiviral assay IC50 values of 0.5 nM against wild-type HIV, 1 nM against the K103N mutant associated with clinical resistance to efavirenz, and 0.7 nM against the Y181C mutant associated with clinical resistance to nevirapine. Compound 70h has also demonstrated relatively low clearance in intravenous pharmacokinetic studies in three species, and it is the active component of a drug candidate which has progressed to phase 2 clinical studies.